Literature DB >> 25616575

Generation of a poor prognostic chronic lymphocytic leukemia-like disease model: PKCα subversion induces up-regulation of PKCβII expression in B lymphocytes.

Rinako Nakagawa1, Milica Vukovic2, Anuradha Tarafdar3, Emilio Cosimo3, Karen Dunn3, Alison M McCaig3, Ailsa Holroyd3, Fabienne McClanahan4, Alan G Ramsay5, John G Gribben4, Alison M Michie6.   

Abstract

Overwhelming evidence identifies the microenvironment as a critical factor in the development and progression of chronic lymphocytic leukemia, underlining the importance of developing suitable translational models to study the pathogenesis of the disease. We previously established that stable expression of kinase dead protein kinase C alpha in hematopoietic progenitor cells resulted in the development of a chronic lymphocytic leukemia-like disease in mice. Here we demonstrate that this chronic lymphocytic leukemia model resembles the more aggressive subset of chronic lymphocytic leukemia, expressing predominantly unmutated immunoglobulin heavy chain genes, with upregulated tyrosine kinase ZAP-70 expression and elevated ERK-MAPK-mTor signaling, resulting in enhanced proliferation and increased tumor load in lymphoid organs. Reduced function of PKCα leads to an up-regulation of PKCβII expression, which is also associated with a poor prognostic subset of human chronic lymphocytic leukemia samples. Treatment of chronic lymphocytic leukemia-like cells with the selective PKCβ inhibitor enzastaurin caused cell cycle arrest and apoptosis both in vitro and in vivo, and a reduction in the leukemic burden in vivo. These results demonstrate the importance of PKCβII in chronic lymphocytic leukemia-like disease progression and suggest a role for PKCα subversion in creating permissive conditions for leukemogenesis. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25616575      PMCID: PMC4380723          DOI: 10.3324/haematol.2014.112276

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  51 in total

1.  Subversion of protein kinase C alpha signaling in hematopoietic progenitor cells results in the generation of a B-cell chronic lymphocytic leukemia-like population in vivo.

Authors:  Rinako Nakagawa; Jae Won Soh; Alison M Michie
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

2.  CLL biology and prognosis.

Authors:  Guillaume Dighiero
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2005

3.  In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells.

Authors:  Bradley T Messmer; Davorka Messmer; Steven L Allen; Jonathan E Kolitz; Prasad Kudalkar; Denise Cesar; Elizabeth J Murphy; Prasad Koduru; Manlio Ferrarini; Simona Zupo; Giovanna Cutrona; Rajendra N Damle; Tarun Wasil; Kanti R Rai; Marc K Hellerstein; Nicholas Chiorazzi
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

4.  TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state.

Authors:  M Herling; K A Patel; J Khalili; E Schlette; R Kobayashi; L J Medeiros; D Jones
Journal:  Leukemia       Date:  2006-02       Impact factor: 11.528

5.  Survival role of protein kinase C (PKC) in chronic lymphocytic leukemia and determination of isoform expression pattern and genes altered by PKC inhibition.

Authors:  Serhan Alkan; Qin Huang; Melek Ergin; Mitchell F Denning; Sucha Nand; Tazeen Maududi; Gladell P Paner; Fulya Ozpuyan; Keith F Izban
Journal:  Am J Hematol       Date:  2005-06       Impact factor: 10.047

Review 6.  The link between PKCalpha regulation and cellular transformation.

Authors:  Alison M Michie; Rinako Nakagawa
Journal:  Immunol Lett       Date:  2005-01-31       Impact factor: 3.685

7.  Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors.

Authors:  M Tan; P Li; M Sun; G Yin; D Yu
Journal:  Oncogene       Date:  2006-01-23       Impact factor: 9.867

8.  B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia.

Authors:  Xiao-jie Yan; Emilia Albesiano; Nicola Zanesi; Sophia Yancopoulos; Alan Sawyer; Egidio Romano; Aleksandar Petlickovski; Dimitar G Efremov; Carlo M Croce; Nicholas Chiorazzi
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-24       Impact factor: 11.205

9.  Protein kinase C alpha but not PKCzeta suppresses intestinal tumor formation in ApcMin/+ mice.

Authors:  Henrik Oster; Michael Leitges
Journal:  Cancer Res       Date:  2006-07-15       Impact factor: 12.701

10.  Redundant role for Zap70 in B cell development and activation.

Authors:  Farnaz Fallah-Arani; Edina Schweighoffer; Lesley Vanes; Victor L J Tybulewicz
Journal:  Eur J Immunol       Date:  2008-06       Impact factor: 5.532

View more
  3 in total

1.  AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival.

Authors:  Emilio Cosimo; Anuradha Tarafdar; Michael W Moles; Ailsa K Holroyd; Natasha Malik; Mark A Catherwood; Jodie Hay; Karen M Dunn; Alan M Macdonald; Sylvie M Guichard; Declan O'Rourke; Michael T Leach; Owen J Sansom; Sabina C Cosulich; Alison M McCaig; Alison M Michie
Journal:  Clin Cancer Res       Date:  2018-12-17       Impact factor: 12.531

Review 2.  Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemia.

Authors:  Narjis Fatima; Kyle R Crassini; Lauren Thurgood; Yandong Shen; Richard I Christopherson; Bryone Kuss; Stephen P Mulligan; Oliver Giles Best
Journal:  Cancer Drug Resist       Date:  2020-05-11

3.  Dual Targeting of Stromal Cell Support and Leukemic Cell Growth by a Peptidic PKC Inhibitor Shows Effectiveness against B-ALL.

Authors:  Paola Fernanda Ruiz-Aparicio; Natalia-Del Pilar Vanegas; Gloria Inés Uribe; Paola Ortiz-Montero; Camila Cadavid-Cortés; Jimmy Lagos; Jessica Flechas-Afanador; Adriana Linares-Ballesteros; Jean-Paul Vernot
Journal:  Int J Mol Sci       Date:  2020-05-25       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.